In vitro and in vivo inhibition of HIV-1 replication by retroviral transfer of TAT-inducible interferon α, β or γ genes : Application to gene therapy for Aids;Inhibition in vitro et in vivo de la replication du VIH1 par transfert retroviral des genes d'interferon α, β ou γ: application a la therapie genique du sida

Annales de Biologie Clinique

Volumn 56, Issue 2, 1998, Pages 167-173

  Leissner, P ^a   Calenda, V ^a   Marigliano, M ^a   Sanhadji, K ^b   Touraine, J L ^b   Pavirani, A ^a   Mehtali, M ^a  

^a TRANSGENE S A   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Aids; Gene therapy; Human IFN; SCID mice

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; GAMMA INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW CULTURE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; LYMPHOCYTE; LYMPHOID CELL LINE; MOUSE; NONHUMAN; PROVOCATION TEST; REVIEW; SCID MOUSE; SYMPTOM; SYNTHESIS; TARGET CELL; VIRUS INHIBITION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERONS; MICE; RETROVIRIDAE; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031957030     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Sorg T, Mehtali M. Gene therapy for Aids. Transfus Sci 1997 ; 18 : 277-89.
2. Sorg T, Leissner P, Calenda V, et al. Thérapie génique des maladies infectieuses : le modèle du sida. médecine/sciences 1996 ; 12 : 13-24.
3. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987 ; 56 : 727-77.
4. Ho DD, Neumann AV, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIVl infection. Nature 1995 ; 373 : 123-6.
5. Francis ML, Meltzer MS, Gendelman HE. Interferons in the persistence, pathogenesis and treatment of HIV infection. AIDS Res Hum Retroviruses 1992 ; 8 : 199-207.
6. Hartshorn KL, Neumeyer D, Vogt MW, Schooley RT, Hirsh MS. Activity of IFNα, β and γ against HIV1 replication in vitro. AIDS Res Hum Retroviruses 1987 ; 3 : 125-33.
7. Degre M, Beck S, Rollag H. Interferon may enhance infection of blood-derived macrophages with HIV-1 in the presence of HIV-positive serum. APMIS 1992 ; 100 : 465-9.
8. Paredes J, Krown SE. Interferon alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome. Int J Immunopharmacol 1991 ; 13 : 77-81.
9. Poli G, Biswas P, Fauci AS. Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Res 1994 ; 24 : 221-3.
10. Lane HC, Davey V, Kovacs JA, et al. Interferon alpha in patient with asymptomatic human immunodeficiency virus infection : a randomized, placebo-controlled trial. Ann Int Med 1990 ; 112 : 805-11.
11. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMlS 1995 ; 103 : 161-79.
12. 2-interferon plus zidovudine in the management of Kaposi's sarcoma associated with HIV infection. J Eur Aca Der Ven 1993 ; 2 : 137-40.
13. Calenda V, Leissner P, Marigliano M, Mehtali M. Gene therapy for HIV infection. Hematol Cell Ther 1996 ; 38 : 1-3.
14. Steffy K, Wong-Staal F. Genetic regulation of HIV. Microbiol Rev 1991 ; 55 : 193-205.
15. 2-interferon. Proc Natl Acad Sci USA 1989 ; 86 : 4958-62.
16. Su Y, Popick W, Pitha PM. Inhibition of HIV type 1 replication by a Tat-activated transduced interferon gene : targeted expression of HIV type 1 infected cells. J Virol 1995 ; 69 : 110-2.
17. Lauret E, Riviere I, Rousseau V, Vieillard V, De Maeyer-Guignard J, De Maeyer E. Development of methods for somatic cell gene therapy directed against viral diseases using retroviral vectors carrying the murine of human interferon β coding sequence : establishment of the antiviral state in human cells. Hum Gene Therapy 1993 ; 4: 567-77.
18. Viellard V, Lauret E, Rousseau V, De Maeyer E. Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express interferon β. Proc Natl Acad Sci USA 1994 ; 91 : 2689-93.
19. Emerman M, Guyader M, Montagnier L, Baltimore D, Muesing MA. The specificity of human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. EMBO J 1987 ; 6 : 3755-60.
20. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, Spector SA. HIV1 infection of human PBL-SCID mice. Science 1991 ; 251 : 791-4.
21. Sanhadji K, Leissner P, Firouzi R, et al. Experimental gene therapy : the transfer of Tat-inducible interferon genes protects human cells against HIVI challenge in vitro and in vivo in severe combined immunodeficient mice. AIDS 1997 ; 11 : 977-86.
22. Miller DA, Rosman GI. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989 ; 7 : 980-90.
23. Mehtali M. Complementation cell lines for viral vectors to be used in gene therapy. Cytotechnology 1996 ; 19 : 43-54.
24. Hansen BD, Nara PL, Maheshwari RK, et al. Loss of infectivity by progeny virus from alpha-interferon treated HIV1-infected T cells is associated with defective assembly of envelope gp120. J Virol 1992 ; 66: 7543-8.
25. Dunbar C, Cottler-Fox M, O'Shaughnessy J, Doren S, Carter C, Nienhuis A. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995 ; 85 : 3048-57.
26. Plavec I, Voytovitch A, Moss K, Webster D, Hanley M, Di Giusto D. Sustained retroviral gene marking and expression in lymphoid and myeloid cells derived from transduced hematopoietic cells. Gene Therapy 1996 ; 3 : 717-24.
27. Havenga M, Hoogerbrugge P, Valerio D, Van Es H. Retroviral stem cell gene therapy. Stem Cells 1997 ; 15 : 162-79.
28. Naldini L, Blömer U, Gallay P, Ory D, Mullingan R, Gage F, Verma I, Trono D. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 1996 ; 272 : 263-7.
29. Hess G, Rossol S, Rossol R, Meyer Z, Buschenfelde K. Tumor necrosis factor and interferon as prognostic markers in HIV infection. Infection 1991 ; 2 : 93-7.
30. Gringeri A, Santagostino E, Cusini M, et al. Absence of clinical, virological, and immunological signs of progression in HIV1-infected patients receiving active anti-interferon alpha immunization : a 30-month follow-up report. J Acquir Immune Defic Syndr 1996 ; 13 : 55-67.
31. Kunzi M, Farzadegan H, Margolick J, Vlahov D, Pitha P. Identification of HIV primary isolates resistant to interferon-α and correlation of prevalence to disease progression. J Inf Dis 1995 ; 171 : 822-8.